Leuven, Belgium - November 13, 2006 - ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, today announced that the U.S. Food and Drug Administration (FDA) completed its review of the Company’s Investigational New Drug (IND) application for microplasmin intraocular injection. The FDA considers the proposed MIVI III (Microplasmin for Vitreous Injection III) trial safe to initiate, and ThromboGenics will proceed with patient recruitment for this study. Preliminary positive results of a Phase IIa clinical trial in Europe demonstrated that Microplasmin could induce PVD (posterior vitreous detachment) to ease vitrectomy surgical procedure.
